ISSN 2097-6046（网络）
ISSN 2096-7446（印刷）
CN 10-1655/R
主管：中国科学技术协会
主办：中华护理学会
中华急危重症护理杂志

中华急危重症护理杂志 >

2026 , Vol. 7 >Issue 7: 841 - 845

DOI: https://doi.org/10.3761/j.issn.2096-7446.2026.07.010

急症护理研究

儿童复发难治性急性B淋巴细胞白血病患儿行多部门协作管理的实践

  • 陈凤云 ,
  • 诸纪华 ,
  • 朱淑贞 ,
  • 王燕青 ,
  • 刘艳梅
展开
  • 1 浙江大学医学院附属儿童医院急诊科 杭州市 310000
    2 浙江大学医学院附属儿童医院护理部 杭州市 310000
    3 浙江大学医学院附属儿童医院血液科 杭州市 310000
陈凤云：女，本科，护师，E-mail：453180064@qq.com
作者贡献声明

陈凤云：研究方案设计及实施、文章撰写；诸纪华：研究指导及支持；朱淑贞、王燕青：研究实施、质量评价；刘艳梅：采集数据与分析

*诸纪华，E-mail：Jihuazhu@zju.edu.cn

收稿日期: 2025-07-20

  网络出版日期: 2026-07-01

收起

The practice of multi-department collaborative management for children with relapsed and refractory acute B lymphoblastic leukemia

  • CHEN Fengyun ,
  • ZHU Jihua ,
  • ZHU Shuzhen ,
  • WANG Yanqing ,
  • LIU Yanmei
Expand
  • 1 Emergency Department， the Children’s Hospital Zhejiang University School of Medicine， Hangzhou 310000， China
    2 Nursing Department， the Children’s Hospital Zhejiang University School of Medicine， Hangzhou 310000， China
    3 Hematology Department， the Children’s Hospital Zhejiang University School of Medicine， Hangzhou 310000， China

Received date: 2025-07-20

  Online published: 2026-07-01

Fold

摘要

回顾分析了6例接受贝林妥欧单抗治疗的急性白血病患儿在多部门协作管理模式下的临床资料，系统探讨该模式对治疗效果和安全性的影响。护理方案整合了病房医护人员对家长培训、急诊科用药流程优化及远程家庭用药支持三大核心模块。结果显示，6例患儿中3例顺利完成治疗；1例出现中心静脉堵管（治疗末期），2例发生过敏反应，经及时溶栓及抗过敏处理后均完成疗程。所有患儿均未出现肿瘤溶解综合征、神经系统症状、严重感染或重要脏器损伤等严重不良反应。多部门协作管理模式在保证达到治疗标准的情况下，显著提升了患儿的治疗依从性及家长的满意度。

关键词： 急性淋巴细胞白血病; 贝林妥欧单抗; 急诊科; 多学科诊疗; 儿童; 护理

本文引用格式

陈凤云 , 诸纪华 , 朱淑贞 , 王燕青 , 刘艳梅 . 儿童复发难治性急性B淋巴细胞白血病患儿行多部门协作管理的实践[J]. 中华急危重症护理杂志, 2026 , 7(7) : 841 -845 . DOI: 10.3761/j.issn.2096-7446.2026.07.010

Abstract

This study retrospectively analyzed the clinical data of six pediatric patients with acute lymphoblastic leukemia（ALL） who underwent blinatumomab therapy under the multi-departmental collaborative management model，and systematically evaluated its impact on treatment efficacy and safety. The integrated nursing protocol comprised three core components，including structured training for caregivers，optimized medication administration workflows in the Emergency Department（ED），and remote home-based medication support. Among the six patients，three achieved successfully completed the treatment. Adverse events included one case of central venous catheter occlusion（occurring at the end of treatment） and two allergic reaction；both were successfully managed with timely thrombolysis and anti-allergy therapy，allowing treatment completion. Notably，no severe adverse reactions—such as tumor lysis syndrome，neurological symptoms，severe infections，or critical organ dysfunction—were observed. The findings demonstrated that the multi-departmental collaborative model significantly enhance treatment adherence in pediatric patients and caregiver satisfaction while maintaining standardized therapeutic quality.

Key words： Acute Lymphoblastic Leukemia; Blinatumomab; Emergency Department; Multi-disciplinary Team; Pediatric; Nursing

参考文献

[1] 汤静燕. 儿童常见肿瘤诊断治疗的进步[J]. 中国小儿血液与肿瘤杂志, 2020, 25(6):313-315.
  Tang JY. Progress in diagnosis and treatment of common tumors in children[J]. J China Pediatr Blood Cancer, 2020, 25(6):313-315.
[2] 洪壹, 刘亢亢, 王宁玲, 等. 外泌体源性miR-181b-5p在儿童急性淋巴细胞白血病中的表达及临床意义[J]. 中国实验血液学杂志, 2023, 31(3):643-648.
  Hong Y, Liu KK, Wang NL, et al. Expression and clinical significance of exosome derived miR-181b-5p in children with acute lymphoblastic leukemia[J]. J Exp Hematol, 2023, 31(3):643-648.
[3] ?liwa-Tytko P, Kaczmarska A, Lejman M, et al. Neurotoxicity associated with treatment of acute lymphoblastic leukemia che-motherapy and immunotherapy[J]. Int J Mol Sci, 2022, 23(10):5515.
[4] 初琪慧, 高彤, 曲素欣, 等. 免疫治疗在复发/难治性急性B淋巴细胞白血病中的应用[J]. 中国药房, 2024, 35(7):886-889.
  Chu QH, Gao T, Qu SX, et al. Application of immunotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia[J]. China Pharm, 2024, 35(7):886-889.
[5] 韦楠, 陈天平, 刘洪军. 嵌合抗原受体T细胞在儿童复发难治性急性淋巴细胞白血病中的研究进展[J]. 中国当代儿科杂志, 2023, 25(2):210-216.
  Wei N, Chen TP, Liu HJ. Recent research on chimeric antigen receptor T cells in children with refractory/relapsed acute lymphoblastic leukemia[J]. Chin J Contemp Pediatr, 2023, 25(2):210-216.
[6] Sigmund AM, Sahasrabudhe KD, Bhatnagar B. Evaluating blinatumomab for the treatment of relapsed/refractory ALL:design,development,and place in therapy[J]. Blood Lymphat Cancer, 2020, 10:7-20.
[7] 陈云. 儿童急性淋巴细胞白血病免疫治疗进展[J]. 中外医学研究, 2022, 20(32):180-184.
  Chen Y. Advances in immunotherapy of pediatric acute lymphob lastic leukemia[J]. Chin Foreign Med Res, 2022, 20(32):180-184.
[8] 李妍姿, 马春霞, 吕海燕. 个性化护理干预对急性淋巴细胞白血病患者贝林妥欧单抗治疗感染风险作用研究[J]. 中国病原生物学杂志, 2025, 20(7):920-924.
  Li YZ, Ma CX, Lü HY. The role of personalized nursing intervention in managing infection risk during blinatumomab treatment in acute lymphoblastic leukemia patients[J]. J Parasit Biol, 2025, 20(7):920-924.
[9] 胡乐, 陆子鹏, 蒋奎荣, 等. 胰体尾切除术后住院时间延长的危险因素分析:一项单中心回顾性研究[J]. 南京医科大学学报(自然科学版), 2025, 45(12):1805-1809,1822.
  Hu L, Lu ZP, Jiang KR, et al. Analysis of risk factors for prelonged hospital stay after distal pancreatectomy:a single-center retrospective study[J]. J Nanjing Med Univ, 2025, 45(12):1805-1809,1822.
[10] 李丹, 王春立, 吴心怡, 等. 儿童血友病家庭治疗需求及影响因素的调查分析[J]. 重庆医学, 2024, 53(21):3300-3304,3311.
  Li D, Wang CL, Wu XY, et al. Survey and analysis of family treatment needs and influencing factors for hemophilia in children[J]. Chongqing Med, 2024, 53(21):3300-3304,3311.
[11] 中华医学会儿科学分会血液学组,《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9):641-644.
  Hematology Group,Pediatric Branch of Chinese Medical Association;Editorial Board of Chinese Journal of Pediatrics. Suggestions on diagnosis and treatment of acute lymphoblastic leukemia in children(fourth revision)[J]. Chin J Pediatr, 2014, 52(9):641-644.
[12] 国家卫生健康委办公厅. 儿童急性淋巴细胞白血病诊疗规范(2018版)(国卫办医函〔2018〕868号)[R]. 北京: 国家卫生健康委办公厅, 2018.
  General Office of the National Health Commission. Diagnosis and treatment specification for childhood acute lymphoblastic leukemia(2018 Edition)(Guoweiban Yihan[2018] No. 868)[R]. Beijing: General Office of the National Health Commission, 2018.
[13] 李晓兰, 刘立鹏, 刘芳, 等. 贝林妥欧单抗治疗儿童复发/难治急性淋巴细胞白血病的安全性及近期疗效分析[J]. 中国当代儿科杂志, 2023, 25(4):374-380.
  Li XL, Liu LP, Liu F, et al. Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia[J]. Chin J Contemp Pediatr, 2023, 25(4):374-380.
[14] Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events(CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermo Sifiliográficas Engl Ed, 2021, 112(1):90-92.
[15] 罗听薇, 宋青青, 张娜, 等. 慢性病患儿居家用药安全管理的研究进展[J]. 护理研究, 2022, 36(24):4431-4434.
  Luo TW, Song QQ, Zhang N, et al. Research progress on home medication safety management for children with chronic diseases[J]. Chin Nurs Res, 2022, 36(24):4431-4434.
[16] Gupta SR, Bricker J, Boyle BM, et al. Outcomes for standardized home and hospital-based infusions of infliximab for children with inflammatory bowel disease[J]. J Pediatr Gas-troenterol Nutr, 2023, 76(6):776-781.
[17] 陈丽兰. 听障儿童阅读理解能力的发展及其对数学计算的影响[J]. 内蒙古师范大学学报(教育科学版), 2025, 38(1):89-97.
  Chen LL. Development of reading comprehension ability of hearing-impaired children and its influence on mathematical calculation[J]. J Inn Mong Norm Univ Educ Sci Ed, 2025, 38(1):89-97.
[18] Armideo E, Froio S, Johnson M, et al. Evidence-based criteria supporting early discharge for pediatric patients with osteosarcoma receiving high-dose methotrexate:a retrospective chart review[J]. J Adv Pract Oncol, 2022, 13(2):143-149.
[19] Lv M, Liu Y, Liu W, et al. Immunotherapy for pediatric acute lymphoblastic leukemia:recent advances and future perspectives[J]. Front Immunol, 2022, 13:921894.
[20] 朱秋皎, 潘涛, 柏振江, 等. CAR-T细胞治疗儿童复发性B系急性淋巴细胞白血病所致细胞因子释放综合征临床分析[J]. 临床儿科杂志, 2022, 40(11):848-853.
  Zhu QJ, Pan T, Bai ZJ, et al. Clinical analysis of severe cytokine release syndrome caused by CAR-T cell therapy in children’s intensive care unit[J]. J Clin Pediatr, 2022, 40(11):848-853.
[21] 黄亮, 王其琼, 陈力, 等. 儿童罕见病多学科诊疗的药学服务模式探索[J]. 中国药房, 2023, 34(8):1000-1004.
  Huang L, Wang QQ, Chen L, et al. Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children[J]. China Pharm, 2023, 34(8):1000-1004.
[22] 杨琇莹, 张丽英, 张超琅. 贝林妥欧单抗治疗急性B淋巴细胞白血病复发患儿的护理[J]. 护理与康复, 2023, 22(4):77-79.
  Yang XY, Zhang LY, Zhang CL. Nursing care on blinatumomab in treatment of relapse of paediatric B-cell acute lymphoblastic leukemia[J]. J Nurs Rehabil, 2023, 22(4):77-79.
[23] 彭思静, 卢婕伦, 王子成, 等. 儿童急性淋巴细胞白血病免疫治疗进展[J]. 实用医学杂志, 2022, 38(23):2903-2907.
  Peng SJ, Lu JL, Wang ZC, et al. A progress on immunotherapy for childhood acute lymphoblastic leukemia[J]. J Pract Med, 2022, 38(23):2903-2907.
[24] Marrapodi MM, Di Paola A, Di Feo G, et al. Novel therapeutic approaches in pediatric acute lymphoblastic leukemia[J]. Int J Mol Sci, 2025, 26(23):11362.
[25] 房恩慧, 管惠, 田金鑫, 等. 家庭干预治疗脑性瘫痪儿童疗效的Meta分析[J]. 中国儿童保健杂志, 2025, 33(12):1358-1366.
  Fang EH, Guan H, Tian JX, et al. Meta-analysis on the efficacy of family interventions for children with cerebral palsy[J]. Chin J Child Health Care, 2025, 33(12):1358-1366.
Options
文章导航

/

〈 〉